Abstract：
Lung cancer, the leading cause of cancer-related deaths globally, remains a pressing health issue despite significant medical advances. The New York Lung Cancer Foundation brought together experts from academia, the pharmaceutical and biotech industries as well as organizational leaders and patient advocates, to thoroughly examine the current state of lung cancer diagnosis, treatment, and research. The goal was to identify areas where our understanding is incomplete and to develop collaborative public health and scientific strategies to generate better patient outcomes, as highlighted in our \"Calls to Action.\" The consortium prioritized 8 different calls to action. These include (1) develop strategies to cure more patients with early-stage lung cancer, (2) investigate carcinogenesis leading to lung cancers in patients without a history of smoking, (3) harness precision medicine for disease interception and prevention, (4) implement solutions to deliver prevention measures and effective therapies to individuals in under-resourced countries, (5) facilitate collaborations with industry to collect and share data and samples, (6) create and maintain open access to big data repositories, (7) develop new immunotherapeutic agents for lung cancer treatment and prevention, and (8) invest in research in both the academic and community settings. These calls to action provide guidance to representatives from academia, the pharmaceutical and biotech industries, organizational and regulatory leaders, and patient advocates to guide ongoing and planned initiatives.
摘要：
肺癌,全球癌症相关死亡的主要原因，尽管医学取得了重大进展，但仍然是一个紧迫的健康问题。纽约肺癌基金会汇集了学术界的专家，制药和生物技术行业以及组织领导者和患者倡导者，彻底检查肺癌诊断的现状，治疗,和研究。目标是确定我们理解不完整的领域，并制定协作公共卫生和科学策略，以产生更好的患者结果，正如我们的“行动呼吁”中所强调的那样。“该联盟优先考虑了8个不同的行动呼吁。这些措施包括（1）制定策略来治愈更多的早期肺癌患者，(2)调查无吸烟史患者肺癌的致癌作用,(3)利用精准医学进行疾病拦截和预防，（4）实施解决方案，向资源不足国家的个人提供预防措施和有效的治疗方法，(5)促进与行业合作收集和共享数据和样本，（6）创建和维护对大数据存储库的开放访问，（7）开发新的免疫治疗剂，用于肺癌的治疗和预防，(8)投资于学术和社区环境中的研究。这些行动呼吁为学术界代表提供指导，制药和生物技术行业，组织和监管领导人，和耐心的倡导者，以指导正在进行和计划的举措。
